Olin is one of the world's best basic materials companies and a leading North American producer of copper alloys, ammunition and chlorine and caustic soda. In 2005, Olin posted sales of approximately $2.4 billion. The company has approximately 5,800 employees working in the United States.
To begin with, Olin spun off to shareholders our former Ordnance and Aerospace divisions as Primex Technologies, Inc.
We also announced the sale of our TDI and ADI isocyanates businesses to Arco Chemical for $565 million in cash.
Olin used the proceeds from the TDI sale and other divestments to repurchase Olin common stock, to pay down debt, and to purchase DuPont's 50% share in Niachlor -- a joint venture chlor alkali plant in Niagara Falls, N.Y. The company also invested in a new chlor alkali plant in McIntosh, Alabama. The new Sunbelt plant was built for $200 million as a joint venture between Olin and Geon, a major Olin customer in the polyvinyl chloride (PVC) market.
In mid-1998, Olin announced that it would spin off its specialty chemical businesses as a separate, publicly traded company.
On February 8, 1999, Olin spun off its specialty chemical businesses as Arch Chemicals, Inc.
2007/5 Olin Corporation to acquire chlor-alkali producer Pioneer
Impact of the Combination
The combination would make Olin the third largest producer of chlor-alkali in North America
Enhanced Operational and
Strengthens Olin’s position in core businesses and adds a strong bleach business in the West
* Sunbelt Chloralkali is a 50:50 joint venture between PolyOne and Olin Corporation
AstraZeneca PLC was formed on 6
April 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. The merger represented the
combination of two companies with similar science-based cultures
and a shared vision of the pharmaceutical industry.
The AstraZeneca Board believes that the merger will improve the combined companies' ability to generate long-term growth and shareholder value through:
Global power & reach in sales and marketing
・ Major primary care presence, particularly in gastrointestinal, cardiovascular and respiratory medicine
・ Leading position in a number of specialist/hospital markets, including oncology and anaesthesia
・ Ability to deliver the potential of existing and future products through the power and reach of a combined global sales and marketing resource
・ Widespread class coverage in key therapy areas, such as cardiovascular and respiratory disease, due to complementary nature of products
Stronger R&D platform for innovation led growth
・ Substantial research and development (R&D) expenditure - over $2.5 billion annually
・ Strong combined development pipeline
・ Potential for further strengthening of the pipeline by enhanced discovery and development capability through greater scale and focus on selected areas and technologies - in particular, complementarity in cardiovascular, respiratory, central nervous system and anaesthesia/ analgesia R&D should help to deliver significant benefits
・ Research partnerships - to supplement its own R&D expertise, AstraZeneca will continue to work with external partners, such as academic institutions and other pharmaceutical companies, to broaden its range of early exploratory research and to allow access to a wider base of scientists and new technologies
Greater financial strategic flexibility
・ Financial strength and scale to give AstraZeneca's management greater strategic flexibility to drive long-term earnings growth
・ Substantial operational efficiencies resulting in cost savings
In 1993, ICI demerged three of its businesses (Pharmaceuticals, Agrochemicals and Specialties) to form a separate company, Zeneca.
At Astra of Sweden
Early in this decade, the organisation of Astra's international marketing was expanded, and several licensing agreements renegotiated to give the company control over the marketing of its products in major markets.
On 6 April 1999, Astra officially merged with Zeneca to form AstraZeneca. The merger represented the combination of two companies with science-based cultures and a shared vision of the pharmaceutical industry.
ICI Completes Acquisition of Unilever Speciality
ICI has completed the acquisition of the Speciality Chemicals businesses of Unilever for a debt free price of $8 billion (£4.9 bn). The businesses are:-
・ National Starch, a world leader in industrial adhesives and number one in specialty starches
・ Quest, one of the world's leading fragrance, food ingredient and flavours companies
・ Unichema, a global leader in oleochemicals
・ Crosfield, a major producer of silicates, zeolites and silicas
Pfizer to acquire Pharmacia Corporation
spin-off of its remaining 84% ownership of Monsanto to its current shareholders.
The roots of Pharmacia Corporation date back almost 150 years to 1853 when a leading Italian pharmacist, Carlo Erba, started his own company, which later became Farmitalia Carlo Erba. This company would later unite with Kabi Pharmacia, which began in 1931. These two companies, along with Pharmacia Aktiebolag, form the three main points of origin for Pharmacia AB, a Swedish-based company.
In 1995, Pharmacia & Upjohn was formed through the merger of Pharmacia AB and The Upjohn Company.
Monsanto was formed in 1901 when a high-school dropout and entrepreneur, John F. Queeny, founded the company in St. Louis, Missouri (USA), and began producing saccharin, an artificial sweetener.
In 1985, G.D. Searle & Co. became the pharmaceutical unit of Monsanto.
Monsanto further defined itself when, in August 1997, shareowners of the company approved the spin-off of its chemical business, Solutia Inc. In less than 100 years, Monsanto established itself as a proven leader in the agricultural and pharmaceutical businesses.
On April 3, 2000, Monsanto and Pharmacia & Upjohn completed a merger creating a dynamic and powerful new competitor in the pharmaceutical industry. This new companyーPharmacia Corporationーis a high-performance competitor.
spin-off of its remaining 84% ownership of Monsanto to its current shareholders. → spin-off
Pfizer to acquire Pharmacia Corporation
Monsanto Company To Acquire Delta And Pine Land Company For $1.5 Billion In Cash
Monsanto Reaches Agreement With U.S. DoJ for Acquisition of Delta and Pine Land Company
BASF and Monsanto Announce R&D and Commercialization Collaboration Agreement in Plant Biotechnology
|1901||John F. Queeny founds the original Monsanto. His wife was Olga Monsanto Queeny. The first product of that company was saccharine.|
|1945||The original Monsanto produces and markets agricultural chemicals, including 2,4D.|
|1960||The Agricultural Division is established.|
|1964||Ramrod herbicide is introduced, beginning the use of Western theme names for the original Monsanto's brands of herbicides.|
|1968||Commercialization of Lasso herbicide in the U.S. begins the trend toward reduced-tillage farming.|
|1976||Roundup herbicide is commercialized in the U.S.|
|1982||Scientists working for the
original Monsanto are the first to genetically modify a
The original Monsanto acquires the Jacob Hartz Seed Co., known for its soybean seed.
|1985||G.D. Searle & Co.
became the pharmaceutical unit of Monsanto.
|1987||The original Monsanto conducts the first U.S. field trials of plants with biotechnology traits.|
|1997||The original Monsanto spins off its industrial chemical and fibers business as Solutia Inc.|
|2000||The original Monsanto enters
into a merger and changes its name to Pharmacia Corporation.
A new Monsanto Company, based on the previous agricultural division of Pharmacia, is incorporated as a stand-alone subsidiary of the pharmaceutical company. (Pharmacia itself eventually becomes a subsidiary of Pfizer, in 2003).
|2002||The new Monsanto Company is spun off from Pharmacia and is now a separate company.|
|2005||Monsanto acquires Seminis, Inc.,
a global leader in the vegetable and fruit seed industry.
Monsanto acquires the Stoneville cotton business, including it's NexGen brand.
Monsanto completes its sale of Monsanto Enviro-Chem Systems Inc. to a new company formed by the Enviro-Chem management team and an outside investor. The new company is MECS, Inc.
As Pharmacia Completes Monsanto
SpinOff, Monsanto CEO Says Company Retains Focus and Strategic
As previously announced, at the close of business today Pharmacia Corporation will distribute its 84-percent stake in Monsanto Company to Pharmacia shareowners via a special stock dividend. This distribution will complete Pharmacia's spinoff of Monsanto and establish Monsanto as a 100-percent publicly traded company.
Aventis Reduces its Shareholding in Rhodia, Retains Economic Interest
Aventis announces today the reduction of its stake in Rhodia to 15.3% from 25.2% following a definitive sale and purchase agreement with Credit Lyonnais concerning 17.8 million Rhodia shares (40% of its Rhodia shareholding).
“This transaction is an important step in our continued focus on our core pharmaceutical activities and reaffirms our commitment to our shareholders to exit the non-core industrial activities. In addition, this transaction is a first step to comply with the requirement to reduce the Aventis shareholding in Rhodia to below 5% by April 2004, pursuant to the 1999 agreement with EU and US antitrust authorities.
May 14, 2003 Financial
In pole position/ PKN Orlen, Poland.
PKN Orlen is the largest chemical establishment in Poland.
The company has the largest refinery in Poland and it is the most efficient of its type in Europe
PKN Orlen holds 75% of Zaklady Azotowe Anwil, which has the biggest polyvinyl chloride (PVC) plant in Poland, and also makes nitrogen fertilizers and polyethylene (PE) packaging, using ethylene from PKN Orlen.
PKN Orlen and Basell have established a 50:50 joint venture (jv) Basell Orlen Poliolefins to construct a 400,000 polypropylene (PP) plant and a 320,000 tonnes/y high density polyethylene (HDPE) plant using the Spheripol and Hostalen Basell technology, and starting up in 1H 2005.
Millennium Chemicals Lyondell and Millennium Announce Agreement to Combine
Chemicals (MCH - NYSE) is one of the leading chemical companies
in the world.
We supply millions of pounds of chemicals each year to manufacturers for use in thousands of consumer and industrial products. In short, we work hard to improve the fundamentals of daily life.
Millennium Chemicals is… 概要
|・||The world's second-largest producer of titanium dioxide (TiO2) and the largest merchant seller of titanium tetrachloride (TiCl4) in North America and Europe.|
|・||A leading producer of fragrance chemicals|
|・||The second-largest producer of acetic acid and vinyl acetate monomer in North America, and through its partnership interest in LaPorte Methanol Company, LP, a partner in a leading U.S.A. producer of methanol.|
|・||A 29.5% owner of Equistar Chemicals, LP, the second-largest producer of ethylene and the third-largest producer of polyethylene in North America.|
Millennium Chemicals' corporate headquarters are located in Red Bank, New Jersey. Millennium Chemicals' global network includes 4,000 employees on five continents. View our directory for a complete listing of office and manufacturing locations.
2004-2-6 Asia Chemical Weekly
Ciba to focus on Asia for all new plants
Asia's fundamental importance to the growth plans of Swiss specialty chemicals company Ciba was underlined here on Tuesday by chairman and chief executive Armin Meyer when he said all future capacity expansions would be concentrated in the region.
Meyer, who was speaking at the company's annual results press conference, said investments in the traditional regions of Europe and the US would focus primarily on maintaining world-class standards and process improvements.
Ciba has budgeted around SF250m ($198m/Euro160m) on annual capital expenditure over the next two to three years, said Meyer. About 60% will be spent on maintaining or improving environmental health and safety, debottlenecking and further automation.
The remaining 40% will be invested in new production lines, mainly in the home and personal care, plastic additives and coating effects segments.
米コーニング 忍耐の成果 赤字でも開発 収益源に成長
コーニングでは現在、世界16 カ国 50 社以上の製造・販売・サービス関連企業などと提携し、拠点を配置しています。
2004/2/17 Novartis 日本
Novartis completes strategic acquisition to strengthen number two position in global medical nutrition business
・ New presence in US retail
medical nutrition channel, access to Japanese market and strong
brand portfolio benefit Novartis Medical Nutrition
Novartis has completed the acquisition of Mead Johnson & Company's global adult medical nutrition business in a USD 385 million cash transaction. No divestments were required to obtain regulatory approval of the deal, which officially closed February 13, 2004.
The acquisition adds strong brands like Boost® , Isocal® and Ultracal® to Novartis Medical Nutrition's portfolio and expands its ability to meet the medical nutritional needs of a growing outpatient and ageing population.
Mead Johnson Nutritionals
Mead Johnson Nutritionals' worldwide leadership in nutrition can be traced back nearly a century - to Edward Mead Johnson himself, the company's namesake and founder. In 1888, the life of E. Mead's baby son, Ted, was in danger because he was not thriving on his feedings and had to be fed a cooked "gruel" mixture. Years later, memory of this experience would inspire E. Mead to develop a product that would eventually lead to today's worldwide leader in infant formula sales, of Enfamil and Enfalac.
E. Mead first co-founded Johnson & Johnson with his brother. After a third brother joined the company, E. Mead decided to pursue other interests and formed the American Ferment Company, which he renamed Mead Johnson & Company in 1905. As he started his company, he explored a variety of products; however, his strongest interest was in scientifically based nutritional products.
Mead Johnson & Company became a wholly owned subsidiary of Bristol-Myers Company (now Bristol-Myers Squibb Company) in 1967. Bristol-Myers Squibb is a diversified worldwide health company. It is a leading maker of innovative therapies for cardiovascular, metabolic and infectious diseases, central nervous system and dermatological disorders, and cancer, as well as osmotic care, wound management, nutritional supplements, and infant formulas.
Bristol-Myers Squibb Plans To Divest U.S. And Canadian Consumer Medicines Business
In 1887 William McLaren Bristol and John Ripley Myers decided to sink $5,000 into a failing drug manufacturing firm called the Clinton Pharmaceutical Company, located in Clinton, New York. The company was officially incorporated on December 13, 1887, with William Bristol as president and John Myers as vice president.
In May 1898 came a new name: Bristol, Myers Company (a hyphen would replace the comma after Myers's death in 1899, when the company became a corporation). Not until 1900 did Bristol-Myers break through into the black -- where it has remained ever since.
In 1856 Edward Robinson Squibb founded a pharmaceutical company in Brooklyn, New York, dedicated to the production of consistently pure medicines.
In 1895 Squibb passed most of the responsibility for managing the firm to his sons, Charles and Edward. The company became known as E.R. Squibb & Sons.
In 1989 Bristol-Myers merged with Squibb, creating a global leader in the health care industry. The merger created what was then the world's second-largest pharmaceutical enterprise.
2005/1/11 Bristol-Myers Squibb
Bristol-Myers Squibb Plans To Divest U.S. And Canadian Consumer Medicines Business
Bristol-Myers Squibb Company
(NYSE:BMY) today announced that it intends to divest its U.S. and
Canadian consumer medicines business. Over the coming weeks, the
company will contact prospective buyers for this business.
The company's consumer medicines businesses in Japan, China, Latin America Europe, Middle East and Africa are not included in this divestiture. These businesses remain an important part of the company's pharmaceutical business within each region.
Bristol-Myers Squibb's primary consumer medicine brands in the U.S. and Canada are ExcedrinR, KeriR, ChoiceR and ComtrexR. For the year ended December 31, 2003, sales of consumer medicines brands in the U.S. and Canada totaled approximately $240 million.
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
Bayer to Acquire Roche Consumer Health
Roche makes offer to acquire all outstanding shares of Genentech
海外会社研究 ロシュ 中外製薬